Cyient Ltd DCF Valuation Share Price April 2026
Founded in 1991 as Infotech Enterprises Limited and rebranded to Cyient in 2014, the company is a mid-cap global engineering and technology solutions provider headquartered in Hyderabad. It operates across two main segments: Digital, Engineering & Technology (DET) — its flagship engine — and Cyient DLM (Design-Led Manufacturing), a listed subsidiary focused on electronics manufacturing.
The DET segment (79% of FY25 revenue, down from 85% in FY23) serves verticals including Aerospace & Defence, Transportation, Energy & Utilities, Connectivity, Semiconductor, Automotive, and Medical Technologies. Cyient is differentiated by deep domain expertise in complex engineering — design, simulation, and embedded software — rather than plain IT services. This engineering-first DNA positions it alongside L&T Technology Services and KPIT Technologies in the ER&D (Engineering R&D) services landscape rather than the mainstream IT services pack.
The company has over 12,000 employees globally and generates approximately $832 million in trailing twelve-month revenue (USD terms). FY26 was characterised by management as a “Stabilisation & Transformation” year — revenue grew modestly, margins compressed, but free cash flow remained strong, enabling the ₹720 crore buyback announced on 23 April 2026.
| Metric (₹ Cr) | FY22 | FY23 | FY24 | FY25 | FY26E |
|---|---|---|---|---|---|
| Revenue | 4,534 | 6,016 | 7,147 | 7,360 | 7,445 |
| Operating Profit (EBITDA) | 651 | 1,003 | 1,303 | 1,143 | ~1,038 |
| EBITDA Margin % | 14.4% | 16.7% | 18.2% | 15.5% | ~13.9% |
| PAT (Consolidated) | ~380 | ~556 | 683 | 616 | 463 |
| EPS (₹) | ~34.2 | ~50.1 | 59.1 | 53.6 | ~41.7 |
| ROE % | ~12% | ~16% | ~18% | 12.8% | ~11% |
| ROCE % | ~14% | ~18% | ~21% | 16.6% | ~14% |
| Dividend (₹/sh) | 15 | 24 | 27 | 30 | No final div* |
Revenue trajectory: Cyient grew revenues at a strong 14.7% CAGR from FY22 to FY25, driven by the post-COVID ER&D spend upcycle, geographic diversification, and the DLM segment ramp-up. FY25–FY26 saw growth moderate to near-flat as aerospace and rail spending cycles paused and DLM experienced a 17% revenue decline in FY26.
Margin compression: EBITDA margins peaked at 18.2% in FY24 and declined to approximately 13.9% in FY26 — a 230bps year-on-year compression — reflecting wage inflation, ramp-up costs in new deals, lower-margin DLM mix, and selective deal wins at competitive pricing. Q4 FY26 standalone EBIT margin was 12.4%.
| Quarterly (₹ Cr) | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q4 FY26E |
|---|---|---|---|---|---|
| Revenue | 1,676 | 1,849 | 1,926 | 1,909 | 1,927 |
| Operating Profit | 265 | 297 | 278 | 298 | ~238 |
| OPM % | 16% | 16% | 14% | 16% | ~12% |
| Net Profit | 148 | 187 | 128 | 186 | 65.5 |
| EPS (₹) | 12.97 | 16.14 | 11.02 | 15.35 | ~5.90 |
| Year | FCF (₹ Cr) | Discount Factor | PV of FCF (₹ Cr) |
|---|---|---|---|
| FY27 | 482 | 0.893 | 430 |
| FY28 | 539 | 0.797 | 430 |
| FY29 | 604 | 0.712 | 430 |
| FY30 | 677 | 0.636 | 430 |
| FY31 | 758 | 0.567 | 430 |
| FY32 | 826 | 0.507 | 419 |
| FY33 | 900 | 0.452 | 407 |
| FY34 | 981 | 0.404 | 396 |
| FY35 | 1,069 | 0.361 | 386 |
| FY36 | 1,165 | 0.322 | 375 |
| Terminal Value | — | 0.322 | 7,520 |
| Enterprise Value | — | — | 11,730 |
| Scenario Metric | Bear FY27 | Base FY27 | Bull FY27 |
|---|---|---|---|
| Revenue (₹ Cr) | 7,200 | 8,100 | 9,200 |
| EBITDA Margin | 11.5% | 14.5% | 17.0% |
| PAT (₹ Cr) | 370 | 545 | 650 |
| EPS (₹) | ~34 | ~50 | ~60 |
| Target P/E | 18–20× | 22–24× | 26–28× |
| Target Price | ₹680–780 | ₹1,060–1,200 | ₹1,320–1,500 |
Engineering Services Recovery: Cyient’s DET segment won 24 large deals in FY25 with a total contract potential of $370.8 Mn. H2 FY26 saw positive YoY growth in order intake across all business lines — a key positive signal. Transportation and Mobility saw notable QoQ and YoY growth in Q4 FY26.
Semiconductor Tailwind: Cyient’s New Growth Areas (NGA) — including Semiconductor, Automotive, and Medical Technologies — are positioned to benefit from the global chip design and embedded electronics boom. Semiconductor revenue grew within DET in FY26 even as the aggregate segment was under pressure.
AI Integration: The company is actively deploying AI-led productivity tools within its delivery model, which management expects to expand margins in FY27–28 as AI-augmented engineering becomes mainstream. This is both a margin lever and a competitive positioning play.
DLM Turnaround: Cyient DLM (NSE: CYIENTDLM) reported a 17% revenue decline in FY26 but recorded a record-high order book and improved Q4 margins (11.7% EBITDA). The DLM segment targets the electronics manufacturing services (EMS) opportunity tied to India’s PLI schemes. A revenue recovery in FY27 is consensus expectation.
Buyback Accretion: The ₹720 Cr buyback at ₹1,125/share, covering 64 lakh shares (~5.76% of equity), will accrete EPS by approximately 4–6% in FY27. Fewer shares outstanding amplify per-share earnings metrics even if absolute PAT growth is modest.
FY27 PAT Growth Consensus: Analysts expect 15–20% PAT growth in FY27 as the engineering spend cycle normalises, large deal ramp-ups monetise, and the DLM segment stabilises. This recovery thesis underpins the 12-month price target range of ₹1,060–₹1,200.
| Forward Estimates | FY26A | FY27E | FY28E |
|---|---|---|---|
| Revenue (₹ Cr) | 7,445 | 8,100–8,500 | 9,200–9,800 |
| EBITDA Margin | ~13.9% | 14.5–15.5% | 15.5–17.0% |
| PAT (₹ Cr) | 463 | 530–580 | 650–720 |
| EPS (₹) — post buyback | ~41.7 | ~50–55 | ~62–68 |
| P/E at CMP ₹951.50 | 22.8× | 17.3–19.0× | 14.0–15.3× |
| Dividend Yield (est.) | 1.7%* | 2.5–3.0% | 2.8–3.5% |
- Large deal ramp-up in Aerospace & Defence (US, Europe) — Cyient has a strong track record in embedded software and certification-heavy work.
- Semiconductor design services scaling up — a $50Bn+ global opportunity with India as a design hub beneficiary.
- DLM revenue recovery in FY27 driven by PLI-linked EMS demand and record order book.
- AI-driven margin expansion — internal deployment of AI tools could lift EBITDA margins 150–200bps by FY28.
- Buyback tender at ₹1,125 creates a near-term floor; EPS accretion of 4–6% in FY27.
- US-India tariff resolution removes an overhang on FII buying in Indian IT/ER&D stocks.
- SMBC or other strategic investor interest in ER&D consolidation could trigger re-rating.
- Margin compression below 12% if large deals come at lower-than-expected pricing or ramp slower.
- DLM continues declining — a 2nd consecutive year of revenue contraction would severely damage sentiment.
- US reciprocal tariff (26%) disrupts ER&D offshoring sentiment and client budgets in core US aerospace/industrial markets.
- Low promoter holding (23.3%) means limited support in a market downturn; high institutional and FII selling risk.
- Prolonged working capital cycle deterioration (up from 41 days to 64 days) could stress free cash flow.
- FY26 PAT of ₹463 Cr significantly below earlier consensus — continued earnings downgrades would erode PE re-rating story.
- Key man risk: MD Krishna Bodanapu’s continued leadership critical to large deal relationships and strategy execution.
| Company | Mkt Cap (₹ Cr) | P/E (TTM) | EV/EBITDA | ROE % | Rev CAGR 3yr | EBITDA Margin | Div Yield | Rating |
|---|---|---|---|---|---|---|---|---|
| Cyient Ltd | ~10,580 | 22.8× | ~14× | 12.8% | 17.6% | 13.9% | 3.2% | Accumulate |
| L&T Technology Services | ~39,000 | 32–38× | ~22× | 28% | 16.8% | 19.5% | 1.2% | Premium peer |
| KPIT Technologies | ~24,000 | 36–42× | ~24× | 32% | 28.4% | 20.2% | 0.5% | Premium peer |
| Tata Elxsi | ~30,000 | 38–46× | ~26× | 36% | 18.1% | 28.0% | 1.1% | Premium peer |
| Birlasoft | ~8,500 | 20–24× | ~12× | 22% | 12.3% | 14.5% | 1.8% | Comparable |
| Mphasis | ~34,000 | 28–32× | ~19× | 24% | 14.2% | 18.2% | 2.2% | Comparable |
| Sector Avg (ER&D) | — | ~29× | ~18× | ~24% | ~16% | ~18% | ~1.5% | — |
Cyient trades at a significant discount to the ER&D peer group on P/E (22.8× vs sector 29×) and EV/EBITDA (~14× vs ~18× sector), reflecting the current margin compression cycle and DLM headwinds. However, its dividend yield of 3.2% is materially superior. The discount appears excessive if the FY27 recovery thesis holds. LTTS and Tata Elxsi command structurally higher multiples due to significantly superior margins (19–28% vs Cyient’s 14%) — Cyient would need margin recovery to 16%+ to justify a re-rating to 26–28× P/E.
Cyient at ₹951.50 offers a compelling risk-reward for investors with a 12–18 month horizon. The stock trades at a 15.4% discount to its own buyback price of ₹1,125 — the most explicit management signal available that intrinsic value is materially higher. FY26 was a margin trough year, with EBITDA compressing from 18.2% (FY24 peak) to ~13.9%, driven by deal ramp costs, DLM headwinds, and conservative pricing in a competitive bidding environment.
The recovery thesis rests on three interlocking catalysts: (1) DET order book monetisation — 24 large deals worth $370.8 Mn won in FY25 should begin contributing meaningfully in FY27; (2) DLM stabilisation — record order book suggests Q1–Q2 FY27 inflection; (3) Buyback EPS accretion of 4–6% boosts per-share metrics without requiring PAT growth. At 17–19× FY27E EPS of ₹50–55, the stock prices in near-zero recovery — an asymmetric opportunity if the ER&D upcycle resumes.
The primary risk is a continuation of margin compression below 12% through FY27. The low promoter holding (23.3%) amplifies downside in a risk-off environment. However, the balance sheet is nearly debt-free, free cash flow was strong at ₹226 Cr in Q4 FY26 alone, and the company has a 30-year track record in deep engineering domains that provide a genuine moat against commoditised IT services competition.
Recommended Strategy: Accumulate in tranches between ₹820–₹960. Target ₹1,060–₹1,200 (base case, 12 months). Participate in buyback tender if eligible. Stop loss at ₹720 on weekly close basis.
CMP ₹951.50 (24 Apr 2026) DCF Fair Value ₹1,055 – ₹1,140 Buyback Reference ₹1,125/share Base Case Target ₹1,060 – ₹1,200 Bull Case Target ₹1,320 – ₹1,500 Bear Case Target ₹680 – ₹780
Upside (Base) +12% to +26% Horizon 12–18 Months Stop Loss ₹720 (weekly)
Disclaimer: This report is produced by Zumedha Equity Research for informational purposes only and does not constitute investment advice, a solicitation, or an offer to buy or sell any securities. The analysis is based on publicly available information and Zumedha’s proprietary DCF and valuation framework. While care has been taken to ensure accuracy, Zumedha makes no representations or warranties as to the completeness, accuracy, or timeliness of the information. Past performance is not indicative of future results. Equity investments are subject to market risk. Readers are advised to conduct their own due diligence and consult a SEBI-registered investment advisor before making any investment decisions. Zumedha Equity Research is not a SEBI-registered research analyst. This report is dated 24 April 2026. | zumedha.com
